CN117100829A - 一种治疗新型冠状病毒感染的中药制剂及其制备方法 - Google Patents
一种治疗新型冠状病毒感染的中药制剂及其制备方法 Download PDFInfo
- Publication number
- CN117100829A CN117100829A CN202310966425.7A CN202310966425A CN117100829A CN 117100829 A CN117100829 A CN 117100829A CN 202310966425 A CN202310966425 A CN 202310966425A CN 117100829 A CN117100829 A CN 117100829A
- Authority
- CN
- China
- Prior art keywords
- traditional chinese
- chinese medicine
- novel coronavirus
- parts
- medicine preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 78
- 238000002360 preparation method Methods 0.000 title claims abstract description 47
- 208000001528 Coronaviridae Infections Diseases 0.000 title claims abstract description 26
- 239000000463 material Substances 0.000 claims abstract description 30
- 239000000843 powder Substances 0.000 claims abstract description 27
- 235000006886 Zingiber officinale Nutrition 0.000 claims abstract description 25
- 235000008397 ginger Nutrition 0.000 claims abstract description 25
- 240000007267 Stephania hernandifolia Species 0.000 claims abstract description 19
- 238000000034 method Methods 0.000 claims abstract description 17
- 238000005303 weighing Methods 0.000 claims abstract description 17
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 16
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 16
- 239000006187 pill Substances 0.000 claims abstract description 16
- 238000001914 filtration Methods 0.000 claims abstract description 15
- 238000004519 manufacturing process Methods 0.000 claims abstract description 15
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 14
- 235000011477 liquorice Nutrition 0.000 claims abstract description 14
- 238000001035 drying Methods 0.000 claims abstract description 11
- 238000002791 soaking Methods 0.000 claims abstract description 11
- 230000008569 process Effects 0.000 claims abstract description 10
- 238000012360 testing method Methods 0.000 claims abstract description 10
- 241001330502 Stephania Species 0.000 claims abstract description 5
- 239000000706 filtrate Substances 0.000 claims abstract description 5
- 230000002829 reductive effect Effects 0.000 claims abstract description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 5
- 244000273928 Zingiber officinale Species 0.000 claims abstract 4
- 239000002994 raw material Substances 0.000 claims description 30
- 229940079593 drug Drugs 0.000 claims description 29
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 24
- 240000006927 Foeniculum vulgare Species 0.000 claims description 8
- 235000004204 Foeniculum vulgare Nutrition 0.000 claims description 8
- 239000008187 granular material Substances 0.000 claims description 8
- 238000007689 inspection Methods 0.000 claims description 8
- 238000004806 packaging method and process Methods 0.000 claims description 8
- 239000012535 impurity Substances 0.000 claims description 7
- 241000721047 Danaus plexippus Species 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 6
- 230000033228 biological regulation Effects 0.000 claims description 4
- 239000007902 hard capsule Substances 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 238000005498 polishing Methods 0.000 claims description 4
- 239000000047 product Substances 0.000 claims description 4
- 238000007873 sieving Methods 0.000 claims description 4
- 238000001694 spray drying Methods 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 238000000605 extraction Methods 0.000 claims description 3
- 208000002193 Pain Diseases 0.000 description 22
- 230000036407 pain Effects 0.000 description 22
- 241000234314 Zingiber Species 0.000 description 21
- 208000024891 symptom Diseases 0.000 description 19
- 230000000694 effects Effects 0.000 description 18
- 206010011224 Cough Diseases 0.000 description 15
- 206010037660 Pyrexia Diseases 0.000 description 15
- 238000011160 research Methods 0.000 description 13
- 206010012735 Diarrhoea Diseases 0.000 description 11
- 210000004072 lung Anatomy 0.000 description 11
- 210000002784 stomach Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 150000007523 nucleic acids Chemical class 0.000 description 10
- 102000039446 nucleic acids Human genes 0.000 description 10
- 108020004707 nucleic acids Proteins 0.000 description 10
- 241000711573 Coronaviridae Species 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 8
- 230000004054 inflammatory process Effects 0.000 description 8
- 230000000144 pharmacologic effect Effects 0.000 description 8
- 210000000952 spleen Anatomy 0.000 description 8
- 235000008216 herbs Nutrition 0.000 description 7
- 230000008961 swelling Effects 0.000 description 7
- 206010068319 Oropharyngeal pain Diseases 0.000 description 6
- 201000007100 Pharyngitis Diseases 0.000 description 6
- 241000700605 Viruses Species 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 230000007812 deficiency Effects 0.000 description 6
- 230000002708 enhancing effect Effects 0.000 description 6
- 230000036039 immunity Effects 0.000 description 6
- 208000011580 syndromic disease Diseases 0.000 description 6
- 206010062717 Increased upper airway secretion Diseases 0.000 description 5
- 206010028748 Nasal obstruction Diseases 0.000 description 5
- 206010039101 Rhinorrhoea Diseases 0.000 description 5
- 239000011248 coating agent Substances 0.000 description 5
- 238000000576 coating method Methods 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 208000017574 dry cough Diseases 0.000 description 5
- 208000026435 phlegm Diseases 0.000 description 5
- 230000035922 thirst Effects 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 206010008479 Chest Pain Diseases 0.000 description 4
- 206010013789 Dry throat Diseases 0.000 description 4
- 206010013954 Dysphoria Diseases 0.000 description 4
- 208000032843 Hemorrhage Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 208000000112 Myalgia Diseases 0.000 description 4
- 208000006673 asthma Diseases 0.000 description 4
- 235000019658 bitter taste Nutrition 0.000 description 4
- 208000034158 bleeding Diseases 0.000 description 4
- 230000000740 bleeding effect Effects 0.000 description 4
- 239000003651 drinking water Substances 0.000 description 4
- 235000020188 drinking water Nutrition 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 238000010792 warming Methods 0.000 description 4
- 208000006820 Arthralgia Diseases 0.000 description 3
- 206010063659 Aversion Diseases 0.000 description 3
- 208000000059 Dyspnea Diseases 0.000 description 3
- 206010013975 Dyspnoeas Diseases 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- 206010035664 Pneumonia Diseases 0.000 description 3
- 241001369613 Stephania tetrandra Species 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 208000001848 dysentery Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 231100000869 headache Toxicity 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 239000002075 main ingredient Substances 0.000 description 3
- 208000015001 muscle soreness Diseases 0.000 description 3
- 208000010753 nasal discharge Diseases 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 2
- 206010010726 Conjunctival oedema Diseases 0.000 description 2
- 241000255925 Diptera Species 0.000 description 2
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 2
- 206010017553 Furuncle Diseases 0.000 description 2
- 208000034507 Haematemesis Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 208000036071 Rhinorrhea Diseases 0.000 description 2
- 241000270295 Serpentes Species 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 206010070863 Toxicity to various agents Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 229940124579 cold medicine Drugs 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 208000001780 epistaxis Diseases 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000003026 hypopharynx Anatomy 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 201000009240 nasopharyngitis Diseases 0.000 description 2
- 231100000956 nontoxicity Toxicity 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 206010042772 syncope Diseases 0.000 description 2
- 231100000820 toxicity test Toxicity 0.000 description 2
- 238000009602 toxicology test Methods 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 231100000611 venom Toxicity 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010002653 Anosmia Diseases 0.000 description 1
- 201000007848 Arts syndrome Diseases 0.000 description 1
- 241001678559 COVID-19 virus Species 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 241000709687 Coxsackievirus Species 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 241000725619 Dengue virus Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 235000017443 Hedysarum boreale Nutrition 0.000 description 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 206010050515 Hyposmia Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 241000218164 Menispermaceae Species 0.000 description 1
- 208000025370 Middle East respiratory syndrome Diseases 0.000 description 1
- 201000010927 Mucositis Diseases 0.000 description 1
- 241000711386 Mumps virus Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010061876 Obstruction Diseases 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 241000218180 Papaveraceae Species 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 1
- 208000004078 Snake Bites Diseases 0.000 description 1
- 241000029486 Stephania sinica Species 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- 208000031975 Yang Deficiency Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940030225 antihemorrhagics Drugs 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004134 energy conservation Methods 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 239000002874 hemostatic agent Substances 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 235000019559 hyposmia Nutrition 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000004416 odontoblast Anatomy 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 235000019633 pungent taste Nutrition 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000008786 sensory perception of smell Effects 0.000 description 1
- 230000014860 sensory perception of taste Effects 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/59—Menispermaceae (Moonseed family), e.g. hyperbaena or coralbead
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/66—Papaveraceae (Poppy family), e.g. bloodroot
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种治疗新型冠状病毒感染的中药制剂,包括以下重量份的组分:千金藤11‑20份,细果角茴香11‑18份,干姜11‑16,甘草11‑14份。本发明还公开了一种治疗新型冠状病毒感染的中药制剂的制备方法,包括以下步骤:S1、备料,按生产指令和工艺配方领取:千金藤、细果角茴香、于姜、甘草;S2、浸泡;S3、提取;S4、过滤;S5、浓缩,对步骤S4中得到的滤液进行减压浓缩至浸膏,浓缩温度为60℃或80℃,蒸气压力为0.04Mpa;S6、干燥,得干膏,将干膏粉碎,得到药粉,其中,干膏的干燥收缩率为16%,水分≤8%;S7、将步骤S6中得到的药粉进行称量,送检验室检验;S8、制丸。
Description
技术领域
本发明涉及一种中药,特别涉及一种治疗新型冠状病毒感染的中药制剂及其制备方法。
背景技术
新型冠状病毒即2019新型冠状病毒,新冠病毒可在复制过程中不断适应宿主而产生突变。患者症状主要表现为发热、干咳、乏力。也有一部分患者以鼻塞、流鼻涕、咽痛、嗅觉和味觉减退或丧失、结膜炎、肌肉疼痛以及腹泻等为主要表现。多数患者预后良好,部分严重病例可出现急性呼吸容迫综合征或脓毒症休克,甚至死亡。
目前我们国家还没有注册审批的中药制剂的治疔新冠病毒的药物。
发明内容
针对上述技术问题,本发明提供了一种治疗新型冠状病毒感染的中药制剂。
为了实现上述目的,本发明的技术方案具体如下:
一种治疗新型冠状病毒感染的中药制剂,包括以下重量份的组分:千金藤11-20份,细果角茴香11-18份,干姜11-16,甘草11-14份。
其中,千金藤为君药,细果角茴香为臣药,干姜为佐药,甘草为使药。
本发明还提供了一种治疗新型冠状病毒感染的中药制剂的制备方法,包括以下步骤:
S1、备料,按生产指令和工艺配方领取:千金藤、细果角茴香、于姜、甘草;
S2、浸泡,称取细果角茴香、千金藤、干姜、甘草,将以上备用的原料合并投入多功能提取器中,按原料的重量加5倍量的60%的食用乙醇浸泡0.5小时;
S3、提取,浸泡到时后,按多功能提取器中物料的重量,加10倍量的60%食用乙醇煎煮2小时,滤出煎液,再加9倍量的60%食用乙醇煎煮2小时,滤出煎液合并,其中,提取温度65~75℃;
S4、离心过滤除杂,将步骤S3中得到的煎液进行过滤除杂;
S5、浓缩,对步骤S4中得到的滤液进行减压浓缩至浸膏,浓缩温度为60℃或80℃,蒸气压力为0.04Mpa;
S6、干燥,得干膏,将干膏粉碎,过80目筛,得到药粉,其中,干膏的干燥收缩率为16%,水分≤8%;
S7、含量检测,将步骤S6中得到的药粉进行称量,送检验室检验;
S8、制丸,将步骤S6中得到的药粉制成0.25g的浓缩丸备用;
S9、干燥 、打光、内包装 、外包装、成品、入库。
其中,所述步骤S1中,各组份全部选用中药饮片,在领料称量时,要先核对原辅料品名是否与配方相符,并核对原辅料检验报告单或原料入库验收单,检查原辅料质量是否符合要求,另外要按规定检查调整衡器,称量时双人复核总量放大100倍备用。
其中,所述步骤S5中,得到的浸膏密度为1.0~1.1。
其中,所述步骤S6中,采用喷雾干燥,其进口温度150℃,出口温度90℃。
其中,所述步骤S8中,将药粉制成片剂或硬胶囊剂或颗粒剂或浓缩丸剂或散剂。
千金藤:为防己科植物千金藤的根茎入药。性寒。味苦,入肺、脾、大肠三经。功效:清热解毒.本品味苦,性寒,入肺胃心经,功可清热泄火,解毒消肿。主治:常可用于咽喉肿痛,毒蛇蚊伤,痛肿恶疮等证。咽喉肿痛,脾胃积热化火,上扰咽喉,而致热毒壅闭性咽喉肿痛。症见咽喉红肿,疼痛剧烈,语言及吞咽困难,颌下结核疼痛,痰鸣气急,牙关紧闭,如肿胀坚硬散漫则无脓,肿胀高突,根脚紧囊顶软则有脓,伴发热,口渴,头痛,脉数,苔黄。本品苦寒,循咽喉,清热解毒且消肿,可治热毒壅闭性咽喉肿痛证。此症状复合新冠病毒感染的临床症状。药理研究:抗炎作用,千金藤提取物口服对人体内的一些炎症,尤其是耳鼻、咽喉、口腔内的炎症也都有很好的效果。口服能使牙酿炎口腔粘膜炎症明显好转,对舌及口唇边炎症也有一定的疗效,尤其能使口腔内溃疡状况改善。大剂量口服千金藤提取物对渗出性中耳炎有效,能使耳鸣、耳内闭塞感减轻或消失,使鼓膜渗出液减少或消失,使听力改善及其它一些症状好转等,近年来又有报道表明,千金藤提取物对各种病毒感染也有一定的治疗作用。民间用于治疗毒蛇咬伤,效果较好,在治疗扁平优、寻常性优、尖锐湿优、皮炎、带状疤疹等也有很好的疗效。此外,千金藤还具有抑制血小板聚集作用;对疼痛刺激有免疫增强效果,显示为一定的镇痛作用等等。动物毒性根据动物急性毒性实验表明:给药千金藤提取物后,小鼠的LD`值分别为:口服2100mg/kg,腹腔注射135mg/k实验表明没有毒性、服用是按全的,千金藤为本处方首选药物,单味使用达不到治疗效果,需配伍使用,根椐药理研究及临床使用的经验,配伍佐药。主要用于抗炎,增强免疫力的做用,四味药相配,相须为用,增强清瘟解毒,解热镇痛,抗炎,增强免疫力,抗病毒,消除发热、疼痛及肺炎的临床体症。
细果角茴香:藏药细果角茴香为罂粟科角茴香属细果角茴香。全草入药,味苦、性寒。归肺、肝、胆经。功效:清热解毒,防瘟疫。主治:用于治疗新冠病毒,流行性感冒,上呼吸道感染,感冒发热,头痛,咽喉疼痛,目赤肿痛,肺炎。药理研究:细果角茴香是藏药、是清热解毒药,具有抗病毒作用,诸多体外实验和临床 实践证明,多数病毒对细果角茴香敏感。如呼吸道病毒(登革热病毒,冠状病毒SARS与MERS,流感病毒、麻疹病毒、流行性腮腺炎 病毒)、肠道病毒(脊灰炎病毒、轮状病毒、柯萨基病毒)等使用藏药细果角茴香治疗可获得较好疗效。藏药细果角茴香具有抗病毒活性,且作用范围较广。因此,从传统中藏药中筛选具有广谱性、低毒副作用、易于代谢、无耐药性等优点 的抗病毒药物已成为抗病毒药物研究开发的热点之一。 藏药细果角茴香为本处方首选药物。单味使用达不到治疗效果,需配伍使用,根椐药理研究及临床使用的经验配伍为臣药,主要用于清瘟解毒. 抗炎镇痛,解热、抗新冠病毒,消除病毒感染的临床症状。
干姜, 味辛;性热。归经:脾;胃;心;肺经。功效:温中散寒;回阳通脉;温肺化饮。主脘腹冷痛;呕吐;泄泻,亡阳厥逆;寒饮喘咳;寒湿痹痛。各家论述:
1.李杲:干姜,生辛炮苦,阳也,生用逐寒邪而发表,炮则除胃冷而守中,多用之耗散元气,辛以散之,是壮火食气故也,须以生甘草缓之。辛热以散里寒,同五味子用以温肺,同人参用以温胃也。
2.干姜,入肺中利肺气,入肾中燥下湿,入肝经引血药生血,同补阴药亦能引血药入气分生血,故血虚发热、产后大热者,用之。止唾血、痢血,须炒黑用之。有血脱色白而夭不泽,脉濡者,此大寒也,宜干姜之辛温以益血,大热以温经。
3.《纲目》:干姜,能引血药入血分、气药入气分。又能去恶养新,有阳生阴长之意,故血虚者用之。凡人吐血、衄血、下血,有阴无阳者,亦宜用之,乃热因热用,从治之法也。
4.《本草正》:下元虚冷,而为腹疼泻痢,专宜温补者,当以干姜炒黄用之。若产后虚热,虚火盛而唾血、痢血者,炒焦用之。若炒至黑炭,已失姜性矣。其亦用以止血者,用其黑涩之性已耳。若阴盛格阳、火不归元及阳虚不能摄血,而为吐血、衄血、下血者,但宜炒熟留性用之,最为止血之要药。
5.《药品化义》:干姜干久,体质收束,气则走泄,味则含蓄,比生姜辛热过之,所以止而不行,专散里寒。如腹痛身凉作泻,完谷不化,配以甘草,取辛甘合化为阳之义。入五积散,助散标寒,治小腹冷痛;入理中汤定寒霍乱,止大便溏泻;助附子以通经寒,大有回阳之力;君参术以温中气,更有反本之功。生姜主散,干姜主守,一物大相迥别。......炮姜,退虚热。
6.《本经》:主胸满咳逆上气,温中,止血,出汗,逐风湿痹,肠僻下痢。生者尤良。
甘草,为豆科植物,甘草入药部位干燥根和茎。味甘,性平。归心、肺、脾、胃经。功效:补脾益气,清热解毒,祛痰止咳,缓急止痛,调和诸药。主治:用于脾胃虚弱、倦怠乏力、心悸气、咳嗽痰多、四肢挛急疼痛、痈肿疮毒、缓解药物毒性和烈性。甘草为本处方首选药物配伍为使药。主要用于缓解药物毒性和烈性。因前三味药清热解毒,性味寒凉,配甘草以防伤胃。
本发明中药制剂4味中药按配伍规则君、臣、佐、使配伍组方。
1.君药千金藤:清热解毒.本品味苦,性寒,入肺胃心经,功可清热泄火,解毒消肿。主治:常可用于咽喉肿痛,毒蛇蚊伤,痛肿恶疮等证清瘟解毒抗炎增强免疫力,
2.臣药细果角茴香:清热解毒,防瘟疫。解热镇痛抗炎增强免疫力,于治疗病毒,流行性感冒,上呼吸道感染,感冒发热,头痛,咽喉疼痛,目赤肿痛,肺炎。
3.佐药干姜:温中散寒;回阳通脉;温肺化饮。主脘腹冷痛;呕吐;泄泻,亡阳厥逆;寒饮喘咳;寒湿痹痛,增强免疫力。
4.使药甘草,补脾益气,清热解毒,祛痰止咳,缓急止痛,调和诸药缓解药物毒性。
配方中前两味药塞凉性烈以伤脾胃,因此配伍温中散寒的干姜保护胃膜。在配伍调和诸药缓解药物毒性的甘草。四味药合理配伍,经科学的制备工艺制成,经药理研究结果表明:本中药制剂具有:抗新冠病毒、抗炎、解热、镇痛的药理作用。临床使用治疗新型冠状病毒感染,轻型和普通型的治愈率达到96%。
本发明的制备方法中,4味中药饮片合并,经科学的制备工艺制成、工艺独特,方法简单, 收率高、生产成本低的特点。处方原料配比重量份及两种提取工艺是本发明的权利要求,该制剂具有见效快、疗效显著、服用安全、治疗范围广,是常规治疗新型冠状病毒感染、轻型和普通型的药物、临床症状,属瘟毒炽盛袭肺证、症见发热,肌肉酸痛,咳嗽胸痛,烦躁口渴,少痰或干咳、气喘,或兼恶寒,或伴鼻塞、流涕或咽干、咽痛,纳少,便溏,舌红,苔薄腻或薄黄腻,脉滑或濡数。服用该制剂一个疔程,以上临床症状基本消除。
附图说明
图1为本发明的工艺流程图。
具体实施方式
为使本发明的目的、技术方案和优点更加清楚明了,下面结合具体实施方式并参照附图,对本发明进一步详细说明。应该理解,这些描述只是示例性的,而并非要限制本发明的范围。此外,在以下说明中,省略了对公知结构和技术的描述,以避免不必要地混淆本发明的概念。
实施例1
一种治疗新型冠状病毒感染的中药制剂,包括以下重量份的组分:千金藤11份,细果角茴香11份,干姜11份,甘草11份。
其中,千金藤为君药,细果角茴香为臣药,干姜为佐药,甘草为使药。
如图1所示,本发明还提供了一种治疗新型冠状病毒感染的中药制剂的制备方法,包括以下步骤:
S1、备料,按生产指令和工艺配方领取:千金藤、细果角茴香、于姜、甘草;
S2、浸泡,称取细果角茴香、千金藤、干姜、甘草,将以上备用的原料合并投入多功能提取器中,按原料的重量加5倍量的60%的食用乙醇浸泡0.5小时;
S3、提取,浸泡到时后,按多功能提取器中物料的重量,加10倍量的60%食用乙醇煎煮2小时,滤出煎液,再加9倍量的60%食用乙醇煎煮2小时,滤出煎液合并,其中,提取温度65℃,提取设备为200型多功能提取机组,生产企业、上海圆通制药设备有限公司;
S4、离心过滤除杂,将步骤S3中得到的煎液进行过滤除杂,设备选取70型自动离心过滤机;
S5、浓缩,对步骤S4中得到的滤液进行减压浓缩至浸膏,浓缩温度为60℃,蒸气压力为0.04Mpa;
S6、干燥,得干膏,将干膏粉碎,过80目筛,得到药粉,其中,干膏的干燥收缩率为16%,水分≤8%,干燥设备为离心式喷雾干燥机,型号为B20型,生产企业为上海圆通制药设备有限公司;
S7、含量检测,将步骤S6中得到的药粉进行称量,送检验室检验;
S8、制丸,将步骤S6中得到的药粉制成0.25g的浓缩丸备用,设备选用全自动制丸机,型号为SB2型,生产企业为上海圆通制药设备有限公司;
S9、干燥 、打光、内包装 、外包装、成品、入库。
其中,所述步骤S1中,各组份全部选用中药饮片,在领料称量时,要先核对原辅料品名是否与配方相符,并核对原辅料检验报告单或原料入库验收单,检查原辅料质量是否符合要求,另外要按规定检查调整衡器,称量时双人复核总量放大100倍备用。
其中,所述步骤S5中,得到的浸膏密度为1.0。
其中,所述步骤S6中,采用喷雾干燥,其进口温度150℃,出口温度90℃。
其中,所述步骤S8中,将药粉还可以制成片剂或硬胶囊剂或颗粒剂或浓缩丸剂或散剂。
本发明中全部选用中药饮片:符合《中华人民共和国药典》2015年版一部相应的要求。由公司质量部门验收合格。饮用水:符合GB5749-2006生活饮用水卫生标准。
实施例2
一种治疗新型冠状病毒感染的中药制剂,包括以下重量份的组分:千金藤20份,细果角茴香18份,干姜16份,甘草14份。
其中,千金藤为君药,细果角茴香为臣药,干姜为佐药,甘草为使药。
如图1所示,本发明还提供了一种治疗新型冠状病毒感染的中药制剂的制备方法,包括以下步骤:
S1、备料,按生产指令和工艺配方领取:千金藤、细果角茴香、于姜、甘草;
S2、浸泡,称取细果角茴香、千金藤、干姜、甘草,将以上备用的原料合并投入多功能提取器中,按原料的重量加5倍量的60%的食用乙醇浸泡0.5小时;
S3、提取,浸泡到时后,按多功能提取器中物料的重量,加10倍量的60%食用乙醇煎煮2小时,滤出煎液,再加9倍量的60%食用乙醇煎煮2小时,滤出煎液合并,其中,提取温度75℃,提取设备为200型多功能提取机组,生产企业、上海圆通制药设备有限公司;
S4、离心过滤除杂,将步骤S3中得到的煎液进行过滤除杂,设备选取70型自动离心过滤机;
S5、浓缩,对步骤S4中得到的滤液进行减压浓缩至浸膏,浓缩温度为80℃,蒸气压力为0.04Mpa;
S6、干燥,得干膏,将干膏粉碎,过80目筛,得到药粉,其中,干膏的干燥收缩率为16%,水分≤8%,干燥设备为离心式喷雾干燥机,型号为B20型,生产企业为上海圆通制药设备有限公司;
S7、含量检测,将步骤S6中得到的药粉进行称量,送检验室检验;
S8、制丸,将步骤S6中得到的药粉制成0.25g的浓缩丸备用,设备选用全自动制丸机,型号为SB2型,生产企业为上海圆通制药设备有限公司;
S9、干燥 、打光、内包装 、外包装、成品、入库。
其中,所述步骤S1中,各组份全部选用中药饮片,在领料称量时,要先核对原辅料品名是否与配方相符,并核对原辅料检验报告单或原料入库验收单,检查原辅料质量是否符合要求,另外要按规定检查调整衡器,称量时双人复核总量放大100倍备用。
其中,所述步骤S5中,得到的浸膏密度为1.1。
其中,所述步骤S6中,采用喷雾干燥,其进口温度150℃,出口温度90℃。
其中,所述步骤S8中,将药粉还可以制成片剂或硬胶囊剂或颗粒剂或浓缩丸剂或散剂。
本发明中全部选用中药饮片:符合《中华人民共和国药典》2015年版一部相应的要求。由公司质量部门验收合格。饮用水:符合GB5749-2006生活饮用水卫生标准。
本发明具有:对于治疗新型冠状病毒感染具有疗效好、疗程短、无毒无明显副作用、服用方便的优点。同时本制备方法工艺独特,方法简单,成本低,节能环保,同时能显著缩短生产周期,降低生产成本及能耗,具有显著的竞争优势和广泛的应用前景。
十、临床资料:
作为治疗新型冠状病毒感染:轻型和普通型,属瘟毒炽盛袭肺证,症见发热,肌肉酸痛,咳嗽胸痛,烦躁口渴,少痰或干咳、气喘,或兼恶寒,或伴鼻塞、流涕,或咽干、咽痛,纳少,便溏,舌红,苔薄腻或薄黄腻,脉滑或濡数。及无症状核酸检测为阳性者。综合征的病例。用本发明中药制剂,选择确诊为核酸检测为阳性者、综合征患者160例临床观察,其中男性110例,女性50例,年龄40-70岁。
十一、治疗方法:口服本发明中药制剂, 规格0.25g/24粒/瓶.每次口服4粒,每日服3次,3天为一疗程,共1-2个疗程。
疗效判定:
1治愈:症状全部消失身体恢复正常。核酸检测为阴性者128例
2显效:症状明显减轻,身体明显好转。核酸检测为阴性者31例
3有效:症状有所减轻,身体有所好转。核酸检测为阴性者1例
4无效:通过治疗后症状无减轻或加重。无
十二、由上述临床验证结果可知,使用本发明中药制剂,治疗新型冠状病毒感染:轻型和普通型、综合征患者160例,取得了较好的临床疗效,治愈128例,显效和有效共32例,无效无,有效率达到98%,对临床治愈人员随机抽查20人,核酸检测均为阴性、未见复发。用药期间未发现局部及全身过敏现象。
典型病例举例:
1、李否显,男,50岁,患者发热,肌肉酸痛,咳嗽胸痛,烦躁、口渴,干咳、气喘,鼻塞、流涕,咽干、咽痛,便溏,舌红,苔薄腻或薄黄腻,脉滑或濡数。核酸检测为阳性、服用感冒药物治疗,服用一段时间后未见任何好转,使用本发明中药制剂,规格0.25g/瓶、每次4粒,开水冲服,服用.2天症状明显好转,服用3天症状消失,身体恢复正常,核酸检测为阴性。
2、俞俊沅,男,60岁,患者发热,肌肉酸痛,咳嗽胸痛,烦躁、口渴,干咳、气喘,鼻塞、流涕,咽干、咽痛,便溏,舌红,苔薄腻或薄黄腻,脉滑或濡数。核酸检测为阳性、服用感冒药物治疗,服用一段时间后未见任何好转,使用本发明中药制剂,规格0.25g/瓶、每次4粒,开水冲服,服用.2天症状明显好转,服用3天症状消失,身体恢复正常,核酸检测为阴性。
十三、本发明中药制剂,治疗新型冠状病毒感染的药物,协作单位3个:1.药理学研究项目:由武汉大学病毒实验室承担,抗新冠病毒动物试验、中药制剂对新冠病毒原始毒殊的病毒抑制率率平均为84%。这项研究取得了重大成果,2.毒理学研究项目由武汉疾病防治控治中心承担研究,主要对本发明制剂分拆研究,及动物急性毒理试验研究和长期毒理试验研究,本项目研究取得了重大成果。3.药学研究项目由武汉中南民族大学承担,对原药材、千金藤、细果角茴香做药理研究,制定标准、有效成份的检测,研究千金解丸的含量捡验方法,质量标难及稳定性研究。本研究项目取得了重大成果。配方及制备工艺的研究成果为本企业所有。
应当理解的是,本发明的上述具体实施方式仅仅用于示例性说明或解释本发明的原理,而不构成对本发明的限制。因此,在不偏离本发明的精神和范围的情况下所做的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。此外,本发明所附权利要求旨在涵盖落入所附权利要求范围和边界、或者这种范围和边界的等同形式内的全部变化和修改例。
Claims (7)
1.一种治疗新型冠状病毒感染的中药制剂,其特征在于,包括以下重量份的组分:千金藤11-20份,细果角茴香11-18份,干姜11-16,甘草11-14份。
2.根据权利要求1所述的一种治疗新型冠状病毒感染的中药制剂,其特征在于:千金藤为君药,细果角茴香为臣药,干姜为佐药,甘草为使药。
3.根据权利要求2所述的一种治疗新型冠状病毒感染的中药制剂的制备方法,其特征在于,包括以下步骤:
S1、备料,按生产指令和工艺配方领取:千金藤、细果角茴香、于姜、甘草;
S2、浸泡,称取细果角茴香、千金藤、干姜、甘草,将以上备用的原料合并投入多功能提取器中,按原料的重量加5倍量的60%的食用乙醇浸泡0.5小时;
S3、提取,浸泡到时后,按多功能提取器中物料的重量,加10倍量的60%食用乙醇煎煮2小时,滤出煎液,再加9倍量的60%食用乙醇煎煮2小时,滤出煎液合并,其中,提取温度65~75℃;
S4、过滤,将步骤S3中得到的煎液进行过滤除杂;
S5、浓缩,对步骤S4中得到的滤液进行减压浓缩至浸膏,浓缩温度为60℃或80℃,蒸气压力为0.04Mpa;
S6、干燥,得干膏,将干膏粉碎,过80目筛,得到药粉,其中,干膏的干燥收缩率为16%,水分≤8%;
S7、含量检测,将步骤S6中得到的药粉进行称量,送检验室检验;
S8、制丸,将步骤S6中得到的药粉制成0.25g的浓缩丸备用;
S9、干燥 、打光、内包装 、外包装、成品、入库。
4.根据权利要求3所述的一种治疗新型冠状病毒感染的中药制剂,其特征在于:所述步骤S1中,各组份全部选用中药饮片,在领料称量时,要先核对原辅料品名是否与配方相符,并核对原辅料检验报告单或原料入库验收单,检查原辅料质量是否符合要求,另外要按规定检查调整衡器,称量时双人复核总量放大100倍备用。
5.根据权利要求3所述的一种治疗新型冠状病毒感染的中药制剂,其特征在于:所述步骤S5中,得到的浸膏密度为1.0~1.1。
6.根据权利要求3所述的一种治疗新型冠状病毒感染的中药制剂,其特征在于:所述步骤S6中,采用喷雾干燥,其进口温度150℃,出口温度90℃。
7.根据权利要求3所述的一种治疗新型冠状病毒感染的中药制剂,其特征在于:所述步骤S8中,将药粉制成片剂或硬胶囊剂或颗粒剂或浓缩丸剂或散剂。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310966425.7A CN117100829A (zh) | 2023-08-02 | 2023-08-02 | 一种治疗新型冠状病毒感染的中药制剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310966425.7A CN117100829A (zh) | 2023-08-02 | 2023-08-02 | 一种治疗新型冠状病毒感染的中药制剂及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117100829A true CN117100829A (zh) | 2023-11-24 |
Family
ID=88811904
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310966425.7A Pending CN117100829A (zh) | 2023-08-02 | 2023-08-02 | 一种治疗新型冠状病毒感染的中药制剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117100829A (zh) |
-
2023
- 2023-08-02 CN CN202310966425.7A patent/CN117100829A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103933425A (zh) | 一种治疗肺癌的中药组合物及其制备方法 | |
CN104524227A (zh) | 一种用于治疗龋齿的中药制剂及制备方法 | |
CN104001045A (zh) | 一种用于治疗犬肺炎的药物及其制备方法 | |
CN111588828A (zh) | 一种治疗新冠病毒和病毒性疾病的中药制剂及制备方法 | |
CN102188687B (zh) | 一种治疗感冒的中药组合物 | |
CN107998256A (zh) | 治疗胃炎的缓释片及其制备方法 | |
CN117100829A (zh) | 一种治疗新型冠状病毒感染的中药制剂及其制备方法 | |
CN104547719A (zh) | 一种治疗毒壅气分型烂喉痧病的中药组合物及其制备方法 | |
CN110812453A (zh) | 一种调气温阳的壮药组合物及其制备方法和应用 | |
CN101234139A (zh) | 一种治疗感冒的中成药及其制备方法 | |
CN104352954A (zh) | 一种抗幽门螺旋杆菌的复方中药配方 | |
WO2015149391A1 (zh) | 一种治疗慢性肠炎的中药制剂及其制备方法 | |
CN103735906A (zh) | 一种治疗干性支气管扩张的中药制剂及其制备方法 | |
CN103705692B (zh) | 一种治疗急性胃肠炎的中药制剂 | |
CN103721028B (zh) | 一种治疗心绞痛的药物及制备方法 | |
CN105770454A (zh) | 一种用于护理感染性呼吸道炎症的中药制剂及制备方法 | |
CN105561007A (zh) | 一种用于治疗小儿流行性感冒的中药制剂及制备方法 | |
CN106806762A (zh) | 一种治疗多痰性支气管扩张症的中药制剂及其制备方法 | |
CN104208380A (zh) | 一种用于治疗败血症的胶囊及制备方法 | |
CN105012775A (zh) | 一种治疗急性乳腺炎的中药 | |
CN104688952A (zh) | 一种治疗膀胱湿热型膀胱癌的中药组合物及其制备方法 | |
CN113117009A (zh) | 一种治疗哮喘的中药制剂及其制备方法 | |
CN103599410B (zh) | 一种治疗麻疹透发不畅的中药 | |
CN103550351A (zh) | 治疗偏头疼的中药组合物及其制备方法 | |
CN118634291A (zh) | 一种治疗多种咳嗽和急慢性支气管哮喘的药物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |